secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2023-04-24T23:59:59+00:00
Accession:  0001711279-23-000025
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech reports positive ocular data from compassionate use of B-VEC in DEB patient
--------------------------------------------------------------------------------

- Topical B-VEC achieved full corneal healing by 3 months and improved visual acuity from hand motion to 20/40 at 7 months.
- No drug-related adverse events observed; treatment was well tolerated in the patient.
- Patient had recurrent cicatrizing conjunctivitis; ocular complications affect >50% of recessive DEB patients.
- Company plans to engage regulators to expand B-VEC utility for ocular DEB manifestations.
- Ongoing preclinical studies evaluating intravitreal and subretinal deliveries for other ocular diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000025/0001711279-23-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000025/krys-20230423.htm
  HTML page:      https://secwatch.observer/filing/0001711279-23-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer